Page 238 - Mployee Wellness Programs News Today

Intus Care, a predictive analytics platform designed to improve care outcomes among geriatric patients, recently closed a $14.1 million Series A funding round. The startup's mission is to improve the way PACE programs use their data so they can maintain and enhance the quality of care they provide to vulnerable seniors.

Rubius Therapeutics was unable to secure financing to carry out its pivot to a new manufacturing process for its red blood cell-based cell therapies. The once high-flying biotech is now exploring options that could include a sale of the business or a merger with another company.

The 2023 Physician Fee Schedule conversion factor — which calculates how much a physician is reimbursed by Medicare for services — changed to $33.06, a $1.55 decrease from 2022 at $34.61. The American Medical Association strongly opposes the cuts.

Carta Healthcare recently closed a $20 million Series B financing round. , The company is a San Francisco-based provider of clinical data solutions, and its mission is to reduce the amount of time clinicians spend on mundane administrative tasks. Carta's technology is currently used at 245 hospitals across 18 health systems — the company will use its new funds to scale its customer base.

Process improvement and advanced technology can also help relieve the staffing burden that medical laboratories are facing.

Emalex Biosciences will use the cash from its Series D financing to conduct a Phase 3 clinical trial for ecopipam, an experimental treatment for Tourette syndrome. Though there drugs are already available for Tourette, Emalex’s drug addresses a different central nervous system target that the biotech believes could offer an edge.

Executives from Huma, Abbott, Smith & Nephew and AliveCor share how they are using real world evidence collection to support remote patient monitoring, maximize patient engagement and navigate the regulatory landscape.

Here are three points to consider for any healthcare system that aims to develop apps that enjoy high adoption and, as a result, improve patients’ lives.

During Q3, digital health's funding fell 36% quarter-over-quarter and 72% from its all-time high during last year’s Q2. The primary driver of this reduction is macro market trends, experts said, though digital health companies need to tie their services more directly to value to get funding in the future.

The financing round was led by Heritage Group, and included participation from the investment arms of insurers, like Cigna Ventures and Trinnovate Ventures of Blue Cross Blue Shield Arizona. It brings Valera's total financing amount to about $70 million.